Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP): A Fundamentally Weighted Stock for Long-Term Investors
The stock of Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) last traded at $0.66, down -1.50% from the previous session. ADAP stock price is now -21.97% away from the 50-day moving average and -40.55% away from the 200-day moving average. The market capitalization of the company currently stands at $169.96M. With the price target of $4, H.C. […]
